Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Alzheimer ’s disease Treatment Market Projected To Grow With Significant CAGR Over The Forecast Peri

Author: Ram Reddy
by Ram Reddy
Posted: May 03, 2018

Global Alzheimer ’s disease Treatment Market : Alzheimer’s disease is a neurodegenerative autoimmune disorder that attacks brain’s nerve cells called neurons leading to cell death and degeneration. The common symptoms involved with Alzheimer’s diseases are disorientation, in cognition, personality and behavioral changes, memory loss and trouble in reading and writing. Alzheimer’s mostly affect the aged population who are 60 years or older which can lead to 60-70% of cases of dementia. The major cause of Alzheimer is genetic disorder and diseases caused by brain degeneration. The diagnostic tests include blood tests, cognitive testing with medical imaging. The risks involved with Alzheimer’s disease can be overcome by physical and mental activities and controlling obesity.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-alzheimers-disease-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

According to the WHO, the rise in geriatric population at a significant growth is affecting the Alzheimer’s disease market positively and the CAGR is also expected to grow. Factors such patent expiration, R & D investments, new entries of generics, increase in the healthcare sectors are expected to push the growth of the Alzheimer’s disease market. In addition to that, newer and better drug discovery, the presence of vast market and buyers will also help the market grow. However, limited and precise diagnosis and detection of the Alzheimer disease, lack of government funding and limited treatment options for drugs and research can hamper the market growth for Alzheimer’s disease.

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-alzheimers-disease-treatment-market/#ulp-c654SbFYO64MsOhu

Alzheimer’s disease treatment market is divided as follows-

1. Drug type

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Others

2. Route of administration

  • Oral
  • Implants
  • Others

3. End-users

Hospital Pharmacies, retail pharmacies and online pharmacies.

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-alzheimers-disease-treatment-market/#ulp-14mlyhjMGhVjZqa3

And lastly, the Alzheimer disease treatment market is divided into geographical regions- North America, Latin America, Europe, Asia-Pacific and the Middle East & Africa. North America is the largest market for the Alzheimer drug usage due to excessive demand. According to the American Alzheimer’s Association, almost 5 million adults are suffering from Alzheimer disease due to increase in geriatric populations. Similarly, Alzheimer’s Association the UK is expected to grow due to more and more patients suffering from dementia contributing to the overall growth of the European Alzheimer’s disease treatment market. Also, a report based on United Nations Population Fund, people over 60 will be 12.3% of the world’s populations which is expected to surpass almost 22% by 2050. Some of the important players in the global Alzheimer’s disease treatment market are Eli Lilly and Company (U.S.), Johnson & Johnson Services Inc., (U.S.), AstraZeneca (U.K.), Pfizer Inc. (U.S.), Forest Laboratories (U.S.), are named to few. In 2014, Eli Lilly and AstraZeneca came together to co-develop a partial treatment beneficial for Alzheimer’s disease.

According to the Centers for Disease Control and Prevention (CDC) and global dominance of the disease among the older population, the cases of Alzheimer disease will be tripled, increasing the numbers to 13.8 million cases by 2050. However, drug failure, FDA rejection, etc. can hamper the market growth of the Alzheimer’s disease treatment market. For e.g. Eli Lilly Solanezumab and Pfizer/Johnson & Johnson’s Bapineuzumab have failed to treat the symptoms during the clinical trials. On the other hand, the positive response and acceptance of FDA approved Cholinesterase inhibitors, and Memantine for the treatment of cognitive symptoms, Namzaric by Allergan are out in the market for the treatment of Alzheimer’s disease. Researchers and drug developmental companies can mask the symptoms but cannot stop the progression of the disease. With more government funding in R & D, in future, there will be newer ways to treat Alzheimer’s disease.

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-alzheimers-disease-treatment-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

About the Author

Website @ https://www.precisionbusinessinsights.com

Rate this Article
Leave a Comment
Author Thumbnail
Please or Join to add a comment.
Author: Ram Reddy

Ram Reddy

Flag of United Kingdom
United Kingdom

Member since: May 02, 2018
Total live articles: 57

Related Articles